DZNep(3-DeazaneplanocinA)---HistoneMethyltransferaseInhibitor

How to Use:

• In vitro:  DZNep was used at 1 µM final concentration in vitro and in cellular assays.
• In vivo: DZNep was IP or IV dosed to mice at 120 mg/kg once per day in the xenograft tumor model of Hep-G2, H358, A549, MDA-MB468, HCT116, CAL-27, HepG2, or HPAC.

Reference:

1. 1. Tseng CK, et al. Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. (1989) J Med Chem. 32(7):1442-6.
2. 2. Tan J, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. (2007) Genes Dev. 21(9):1050-63.
3. 3. Miranda TB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. (2009) Mol Cancer Ther. 8(6):1579-88.
4. 4. He S, et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. (2012) Blood. 119(5):1274-82.
5. 5. Hou P, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. (2013) Science. 341(6146):651-4.